Company Analysis

Verastem, Inc. (VSTM)

Nasdaq: VSTM · Pharmaceutical Preparations · Needham, MA · filing with the SEC since 2011
Grade5.3
◀ Past 5.6● Present 3.9▶ Future 6.8
1 est.

The grade of Verastem, Inc.

Nine metrics read from its own filings, by tense
Headline grade
5.3/10
◀ Past5.630% of the headline
● Present3.940% of the headline
▶ Future6.830% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.6/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
5.0/10

Has it survived what it has been through?

1 warning event since 2017; the latest 2022-11-09.

weight 33% of this tense · 50th percentile among 497 sector filers · read for itself

From the record

Verastem, Inc.'s filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2022-11-09) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
7.5/10

What has it actually done, year after year?

+97% a year over 4 filed years; profitable in 0 of 5.

weight 45% of this tense · 75th percentile among 323 sector filers · read for its customers

From the record

Verastem, Inc.'s 4 filed years say what it did: revenue went from $2 million in fiscal 2021 to $31 million in fiscal 2025, up 97% a year; it rose in 3 of 3 years; it never fell from a peak; net income was positive in 0 of 5 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span97.0%top 11% of its family
  • the share of years revenue rosetop 8% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak0.0%top 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
2.8/10

How has it treated the people who own it?

SI estimate 2.8/10, confidence 35 of 100 (one part).

weight 22% of this tense · 28th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 28% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Verastem, Inc.'s shareholder treatment is put at 2.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 28% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.9/1040% of the headline grade · 3 of 3 filed

Financial health

as filed
1.7/10

Is it financially healthy right now?

ROE -366%: lost 366¢ per shareholder dollar. Leverage 77%: owes 77¢ per asset dollar.

weight 45% of this tense · 17th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Verastem, Inc. lost about 366 cents for every dollar of shareholders' money. Leverage: it owed about 77 cents per dollar of assets, and net share issuance: its share count grew 94.1% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 18% of its family
  • return on equitybottom 7% of its family
  • the share count against the year beforebottom 25% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
5.7/10

How strong is its position in its industry?

top 43% of 315 in its family; net margin -677.6%.

weight 33% of this tense · 57th percentile among 315 sector filers · read for its customers

From the record

Verastem, Inc.'s standing among 315 graded names in its industry family: revenue of $31 million in fiscal 2025 ranks in the bottom 50% by size; a net margin of -677.6% ranks in the bottom 34%; revenue growth of 97% a year over the last 3 filed years ranks in the top 14% (its annual reports).

What it rests on

  • revenue against the family$30.9Mtop 50% of its family
  • net margin-677.6%bottom 34% of its family
  • three-year revenue growth97.0%top 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
5.7/10

What are the people in charge doing?

top 43% of 315 in its family for leadership; chief executive since 2023.

weight 22% of this tense · 57th percentile among 315 sector filers · read for its shareholders

From the record

Verastem, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Paterson, Dan (President and CEO, as filed), filing under that title since 2023-08-04, 3.3 years (bottom 36% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 6 years (top 43%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (top 23%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge3 in three years among 12 peopletop 23% of its family
  • the median years the people in charge have filed6.0 yearstop 43% of its family
  • the chief executive's years on the record3.3 yearsbottom 36% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

6.8/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed
6.2/10

How much room does it have to grow?

top 38% of 273 in its family for room to expand.

weight 45% of this tense · 62nd percentile among 273 sector filers · read for itself

From the record

Verastem, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $205 million against no long-term debt tagged leaves 83.2% of its assets as net cash, top 16% of its family; cash from operations less capital spending is -444.8% of revenue (bottom 36%); research spending of 370.7% of revenue (top 34%) (its annual report).

What it rests on

  • cash less debt against assets83.2%top 16% of its family
  • cash from operations less capital spending against revenue-444.8%bottom 36% of its family
  • research spending against revenue370.7%top 34% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
7.9/10

What could actually drive growth from here?

top 21% of 306 in its family for growth drivers.

weight 33% of this tense · 79th percentile among 306 sector filers · read for its customers

From the record

Verastem, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 97% a year over the last three filed years against 97% over all 4, speeding up (top 40% of its family); the newest year grew 209.4% (top 11%); research spending grew 31.4% a year (top 13%); capital spending grew 31.9% a year (top 19%) (its annual reports). Verastem, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span+0.0 points a yeartop 40% of its family
  • the newest year's revenue growth209.4%top 11% of its family
  • three-year growth of research spending31.4%top 13% of its family
  • three-year growth of capital spending31.9%top 19% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
6.1/10

Did its newest year beat what its own record pointed to?

top 39% of 233 in its family for expectations against reality.

weight 22% of this tense · 61st percentile among 233 sector filers · read for its shareholders

From the record

Verastem, Inc.'s newest year against its own record: revenue of $31 million in fiscal 2025 came in 82.4% above the $17 million its prior three years' pace pointed to (top 16% of its family); net income of $209 million against a prior three-year average of $92 million (bottom 13%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 12%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace82.4%top 16% of its family
  • net income against the prior three years' average-128%bottom 13% of its family
  • net margin against its prior averageup more than 100 pointstop 12% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton VSTM · research, not advice